Your browser doesn't support javascript.
loading
Prevention of ICU-acquired infection with decontamination regimen in immunocompromised patients: a pre/post observational study.
Massart, Nicolas; Dupin, Clarisse; Legris, Eleonore; Legay, François; Cady, Anne; Fillatre, Pierre; Reizine, Florian.
Afiliação
  • Massart N; Service de Réanimation, CH de St BRIEUC, 10, Rue Marcel Proust, 22000, Saint-Brieuc, France. nicolasmassart@hotmail.fr.
  • Dupin C; Service de Microbiologie, CH de St BRIEUC, 10, Rue Marcel Proust, 22000, Saint-Brieuc, France.
  • Legris E; Service de Pharmacie, CH de St BRIEUC, 10, Rue Marcel Proust, 22000, Saint-Brieuc, France.
  • Legay F; Service de Réanimation, CH de St BRIEUC, 10, Rue Marcel Proust, 22000, Saint-Brieuc, France.
  • Cady A; Service de Microbiologie, CH de Vannes, 20 bvd général maurice guillaudot, 56000, Vannes, France.
  • Fillatre P; Service de Réanimation, CH de St BRIEUC, 10, Rue Marcel Proust, 22000, Saint-Brieuc, France.
  • Reizine F; Service de Réanimation, CH de Vannes, 20, Bd Maurice Guillaudot, 56000, Vannes, France.
Eur J Clin Microbiol Infect Dis ; 42(10): 1163-1172, 2023 Oct.
Article em En | MEDLINE | ID: mdl-37597052
ABSTRACT

PURPOSE:

Although the proportion of immunocompromised patients admitted to the ICU is increasing, data regarding specific management, including acquired infection (ICU-AI) prophylaxis, in this setting are lacking. We aim to investigate the effect of multiple-site decontamination regimens (MSD) in immunocompromised patients.

METHODS:

We conducted a prospective pre-/post-observational study in 2 ICUs in Bretagne, western France. Adults who required mechanical ventilation for 24 h or more were eligible. During the study period, MSD was implemented in participating ICUs in addition to standard care. It consists of the administration of topical antibiotics (gentamicin, colistin sulfate, and amphotericin B), four times daily in the oropharynx and the gastric tube, 4% chlorhexidine bodywash once daily, and a 5-day nasal mupirocin course.

RESULTS:

Overall, 295 immunocompromised patients were available for analysis (151 in the post-implementation group vs 143 in the pre-implementation group). Solid organ cancer was present in 77/295 patients while immunomodulatory treatments were noticed in 135/295. They were 35 ICU-AI in 29/143 patients in the standard-care group as compared with 10 ICU-AI in 9/151 patients in the post-implementation group (p < 0.001). In a multivariable Poisson regression model, MSD was independently associated with a decreased incidence of ICU-AI (incidence rate ratio = 0.39; 95%CI [0.20-0.87] p = 0.008). There were 35/143 deaths in the standard-care group as compared with 22/151 in the post-implementation group (p = 0.046), this difference remained in a multivariable Cox model (HR = 0.58; 95CI [0.34-0.95] p = 0.048).

CONCLUSION:

In conclusion, MSD appeared to be associated with improved outcomes in critically ill immunocompromised patients.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Descontaminação / Hospedeiro Imunocomprometido Tipo de estudo: Guideline / Observational_studies / Risk_factors_studies Limite: Adult / Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Descontaminação / Hospedeiro Imunocomprometido Tipo de estudo: Guideline / Observational_studies / Risk_factors_studies Limite: Adult / Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article